SMC decisions for November 2011

The Scottish Medicines Consortium (SMC) has accepted the following for use within NHS Scotland:

  • golimumab (Simponi) for restricted use in the treatment of rheumatoid arthritis in combination with methotrexate. It should be given only in accordance with British Society for Rheumatology guidance at a dose of 50mg once monthly.
  • ranibizumab (Lucentis) for restricted use in the treatment of macular oedema secondary to central retinal vein occlusion. It is not accepted for the treatment of macular oedema secondary to branch retinal vein occlusion.
  • paliperidone palmitate (Xeplion) for the maintenance treatment of schizophrenia in adults stabilised on paliperidone or risperidone.

Rejected submissions

The SMC rejected cabazitaxel (Jevtana) for the treatment of hormone-refractory metastatic prostate cancer and naproxen + esomeprazole (Vimovo) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of NSAID-associated peptic ulcers, following full submissions.

Aprepitant (Emend) was rejected for the prevention of chemotherapy-associated nausea and vomiting, following a resubmission.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases